USFDA concludes Cadila Healthcare’s (Zydus) Pharmez facility with one observation

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to the Indian Bourses, on Wednesday, Ahmedabad headquartered Pharma major Cadila Healthcare (Dr Pankaj Patel led Zydus Cadila Group) Ltd said of one of their units being inspected by US Food & Drugs Administration (USFDA) and the regulator has concluded the inspection with one observation.

USFDA inspected the Company‘s formulations manufacturing facility located at Pharmez, Ahmedabad from 25th  March 2019 to 2nd April 2019.

The inspection which included product specific pre-approval and post—approval inspections and a GMP Inspection, concluded with one observation.

The Company is confident of addressing the observation at the earliest.

For more details, click the link, given here :


FacebookGoogle+LinkedinTwitterYouTube, Blogspot, Telegram, Instagram 


Do NOT follow this link or you will be banned from the site!